$BLU News
Last published 3y ago
- 3y agoBLUGSKTSX:BLUBELLUS Health Inc. Announces Voting Results from Special Meeting of ShareholdersBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced the positive outcome of the BELLUS shareholders ("Shareholders") vote at this morning's special meeting of the Shareholders (the
- 3y agoBLUEvaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant - NCT05899829ClinicalTrials.govMeasurement of the area under the plasma concentration by time curve (AUC0-inf), Measurement of the area under the plasma concentration by time curve (AUC0-t), Measurement of the maximum observed plasma drug concentration (Cmax)
- 3y agoBLUGSKTSX:BLUBELLUS Health Inc. Calls Special Shareholders' Meeting in Connection with GSK AcquisitionBusiness WireSpecial Meeting to be held on June 16, 2023 BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other
- 3y agoBLUGSKTSX:BLUBELLUS Health Reports First Quarter 2023 Financial Results and Business HighlightsBusiness Wire- Announced agreement to be acquired by GSK for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion and a premium of approximately 103%; transaction expected to
- 3y agoBLUTSX:BLUBELLUS Health Announces Meeting UpdatesBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the
- 3y agoBLUTSX:BLUBELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release FormulationBusiness WireOnce-daily Extended-Release formulation demonstrated equivalent bioavailability to twice-daily Immediate Release formulation Extended-Release formulation was well tolerated, with the safety profile consistent with
- 3y agoBLUTSX:BLUBELLUS Health Reports Year 2022 Financial Results and Business HighlightsBusiness Wire- Patient enrollment ongoing in the CALM Phase 3 program with topline data expected for CALM-1 in the second half of 2024 - - Ended year with US$337.1 million in cash, cash equivalents and short-term investments; cash
- 3y agoBLUTSX:BLUBELLUS Health to Participate in the Cowen 43rd Annual Health Care ConferenceBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough
- 3y agoBLUTSX:BLUBELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual MeetingBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough
- 3y agoBLUGKOSINSPNTLAOnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of DirectorsPR NewswireNEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial
- 3y agoBLUTSX:BLUBELLUS Health Reports Third Quarter 2022 Financial Results and Business HighlightsBusiness Wire- Initiated CALM Phase 3 program with topline data expected for CALM-1 and CALM-2 in the second half of 2024 and 2025, respectively - - Ended third quarter 2022 with US$364.4 million in cash, cash equivalents and
- 4y agoBLUTSX:BLUBELLUS Health to Participate in Two Upcoming Healthcare Investor ConferencesBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough
- 4y agoBLUA 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2) - NCT05600777ClinicalTrials.gov24-Hour Cough Frequency, Change from Baseline in Cough Severity Visual Analogue Scale at Week 24, Percentage of Participants With ≥ 30mm Reduction, ≥ 20mm Reduction From Baseline in Cough Severity Visual Analog Scale (VAS) at Week 24, (and 3 more...)
- 4y agoBLUTSX:BLUBELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual MeetingBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough
- 4y agoBLUTSX:BLUBELLUS Health to Present at the H.C. Wainwright Global Investment ConferenceBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, tod
- 4y agoBLUTSX:BLUBELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022Business WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, tod
- 4y agoBLUTSX:BLUBELLUS Health Reports Second Quarter 2022 Financial Results and Business HighlightsBusiness Wire- Completed positive End-of-Phase 2 meeting with the Food and Drug Administration ("FDA") and received scientific advice from the European Medicines Agency ("EMA") to support design of its CALM Phase 3 program, which is expected to initiate in Q4 2022 -
- 4y agoBLUTSX:BLUBELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United StatesBusiness WireBELLUS Health Inc. (NASDAQ:BLU)(TSX:BLU) (the "Company" or "BELLUS Health") announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the "Offering") of 16,540,541 common shares at a pri
- 4y agoBLUTSX:BLUBELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United StatesBusiness WireCommon Shares Priced at US$9.25 per Share In connection with its previously announced public offering of common shares in Canada and the United States (the "Offering"), BELLUS Health Inc. ("BELLUS Health" or the "Company") (NASDAQ:BLU) today announce
- 4y agoBLUTSX:BLUBELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United StatesBusiness WireBELLUS Health Inc. ("BELLUS Health" or the "Company") (NASDAQ:BLU), announced today the filing of a preliminary prospectus supplement (the "Supplement") to its amended and restated short form base shelf prospectus dated December 14, 2021, amending and r
- 4y agoBLUTSX:BLUBellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic CoughBusiness Wire- CALM Phase 3 program consists of two pivotal trials (CALM-1 and CALM-2), with primary efficacy endpoint of 24-hour cough frequency measured at 12- and 24-weeks, respectively - - The Company has reached alignment with FDA on the primary efficacy end
- 4y agoBLUTSX:BLUBELLUS Health to Participate in the William Blair Biotech Focus ConferenceBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, tod
- 4y agoBLUTSX:BLUBELLUS Health to Participate in the Jefferies Healthcare ConferenceBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, tod
- 4y agoBLUTSX:BLUBELLUS Health Reports First Quarter 2022 Financial Results and Business HighlightsBusiness Wire- End-of-Phase 2 meeting with the U.S. Food and Drug Administration ("FDA") scheduled for June of 2022; Plan to initiate the Phase 3 program in the second half of 2022 - - Three late-breaking abstracts reviewing clinical data from the Phase 2b SOOTHE
- 4y agoBLUTSX:BLUBELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International ConferenceBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, tod
- 4y agoBLUTSX:BLUBELLUS Health to Participate in Multiple Upcoming Investor ConferencesBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, tod
- 4y agoBLUTSX:BLUBELLUS Health to Participate in the Cowen & Co. 42nd Annual Health Care ConferenceBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, tod
- 4y agoBLUTSX:BLUBELLUS Health Reports Year 2021 Financial Results and Business HighlightsBusiness Wire- Announced positive topline results from the Phase 2b SOOTHE clinical trial in refractory chronic cough ("RCC"), positioning BLU-5937 as a potentially best-in-class P2X3 antagonist - - Plans to request an End-of-Phase 2 meeting with the Food and Dru
- 4y agoBLUMass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937 - NCT05244759ClinicalTrials.govMass balance recovery of total radioactivity in all excreta after a single oral dose of [14C]-BLU-5937
- 4y agoBLUTSX:BLUBELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United StatesBusiness WireBELLUS Health Inc. (NASDAQ:BLU)(TSX:BLU) (the "Company" or "BELLUS Health") announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the "Offering") of 25,000,000 common shares at a pri
- 4y agoBBBLUGMTXOCGN+1Thinking about buying stock in BELLUS Health, Gemini Therapeutics, BlackBerry, Reliance Global Group, or Ocugen?PR NewswireNEW YORK, Dec. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLU, GMTX, BB, RELI, and OCGN. To
- 4y agoBLUTSX:BLUBELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United StatesBusiness WireCommon Shares Priced at US$8.00 per Share In connection with its previously announced public offering of common shares in Canada and the United States (the "Offering"), BELLUS Health Inc. ("BELLUS Health" or the "Company") (NASDAQ:BLU) today announce
- 4y agoBLUTSX:BLUBELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United StatesBusiness WireBELLUS Health Inc. ("BELLUS Health" or the "Company") (NASDAQ:BLU), announced today the filing of a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated December 23, 2020 (the "Base Prospectus") in connectio
- 4y agoARNABLUBLUEFHTX+1Thinking about buying stock in Arena Pharmaceuticals, Bellus Health, Foghorn Therapeutics, Hexo Corp, or bluebird bio?PR NewswireNEW YORK, Dec. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARNA, BLU, FHTX, HEXO, and BLUE. T
- 4y agoBLUTSX:BLUBELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic CoughBusiness WirePrimary efficacy endpoint statistically significant with 34% placebo-adjusted reduction in 24-hour cough frequency observed at 50 mg and 200 mg BID doses (p ≤ 0.005) BLU-5937 was well-tolerated with a low rate of taste-related adverse events (≤6.
- 5y agoBLUTSX:BLUBELLUS Health Reports Third Quarter 2021 Financial Results and Business HighlightsBusiness Wire- Announced positive findings from the Phase 2b SOOTHE trial administrative interim analysis, with at least one dose of BLU-5937 meeting the threshold for a high probability of clinical efficacy - - Phase 2b SOOTHE and Phase 2a BLUEPRINT trials are f
- 5y agoBLUTSX:BLUBELLUS Health to Participate in Two Upcoming Healthcare Investor ConferencesBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, t
- 5y agoBLUTSX:BLUBELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937Business Wire- Live webcast to be held on November 15th at 12:00 p.m. EST – BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chr
- 5y agoBLUTSX:BLUBELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic DermatitisBusiness WireTopline results from both studies are expected in December 2021 BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chro
- 5y agoBLUGGALITMRKTOS+1Thinking about buying stock in BELLUS Health, Grupo Financiero Galicia, Itamar Med, Kratos Defense & Security, or Monopar Therapeutics?PR NewswireNEW YORK, Sept. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLU, GGAL, ITMR, KTOS, and MNPR.
- 5y agoBLUTSX:BLUBELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic CoughBusiness WireInterim analysis met the threshold for a high probability of clinical efficacy Data from interim analysis support accelerated planning for the Phase 3 program SOOTHE Phase 2b trial is on track to deliver topline results in Q4 2021 BELLUS Healt
- 5y agoBLUTSX:BLUBELLUS Health to Present at the H.C. Wainwright Global Investment ConferenceBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, t
- 5y agoBLUTSX:BLUBELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021Business WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, t
- 5y agoBLUTSX:BLUBELLUS Health to Participate in the Jefferies Virtual Healthcare ConferenceBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, t
- 5y agoBLUTSX:BLUBELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare ConferenceBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, t
- 5y agoBLUTSX:BLUBELLUS Health Reports First Quarter 2021 Financial Results and Business HighlightsBusiness Wire- Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials on track, with topline results expected Q4 2021 - - Ended quarter with US$81.9 million in cash, cash equivalents and short-term investments; current cash position expected to be sufficient to f
- 5y agoBLUTSX:BLUBELLUS Health to Present at the American Thoracic Society 2021 International ConferenceBusiness WireBELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, t
- 5y agoBLUBELLUS Health to Present at the Bloom Burton & Co. Healthcare Investor ConferenceBusiness WireLAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overvi ...
- 5y agoBLUBELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of DirectorsBusiness WireLAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of William Mezzanotte, MD, MPH to its Board of Directors. Dr. Mezzanotte brings decades of vast develop ...
- 5y agoBLUBELLUS Health Reports Year 2020 Financial Results and Business HighlightsBusiness WireLAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the year ending December 31, 2020.